Ratings Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
139.4 USD +0.24% Intraday chart for Neurocrine Biosciences, Inc. +0.60% +5.83%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The firm trades with high earnings multiples: 29.61 times its 2024 earnings per share.
  • With an enterprise value anticipated at 5.23 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+5.83% 13.84B
C+
+1.10% 105B
B+
+9.29% 104B
B+
-3.00% 22.09B
B
-11.89% 21.98B
B+
-26.59% 20.17B
A-
-5.20% 19.49B
A-
-6.58% 17.75B
B
+7.46% 11.64B
D
+28.56% 11.55B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes